Opinion

Vincent Rajkumar: The Most Impressive Myeloma Abstract at ASCO 2025

Vincent Rajkumar/X

May 26, 2025, 08:29

Vincent Rajkumar: The Most Impressive Myeloma Abstract at ASCO 2025

Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, shared a post on X:

“The most impressive myeloma abstract at ASCO25

Outstanding longterm efficacy with cilta-cel CAR-T.

5 year survival rate 50%
5 year PFS rate of 33%

Astounding given multi-drug relapsed refractory setting.

Will be interesting to see if there is a plateau in the PFS curve. Will be important to see the data on longterm side effects. But overall these are great results. Patients have commented that for the first time since myeloma diagnosis they are able to lead a normal life off all meds for many years.”

Abstract Title: Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Authors: Peter Voorhees, Tom Martin, Yi Lin, Adam Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesus Berdeja, Binod Dhakal, Andrzej Jakubowiak, Samir Parekh, Hui Li, Rocio Montes de Oca, Huabin Sun, Nikoletta Lendvai, Deepu Madduri, Mythili Koneru, Nitin Patel, Sundar Jagannath

Read Full Abstract on ASCO.

Myeloma Abstract

More posts featuring ASCO 2025.

Abhinav Deol Adam Cohen Andrzej Jakubowiak Binod Dhakal cancer Deepu Madduri Huabin Sun Hui Li Jesus Berdeja Mounzer Agha Myo Htut Mythili Koneru Nikoletta Lendvai Nitin Patel Noopur Raje OncoDaily Oncology Peter Voorhees Rocio Montes de Oca Samir Parekh Sundar Jagannath Tom Martin Vincent Rajkumar Yi Lin

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action

King Hussein Cancer Research Award: Don’t Miss Your Chance to Apply